canvuparatide
canvuparatide: developed by 1 company · 1 clinical trial tracked.
canvuparatide evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could canvuparatide → MBX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| MBX Biosciences, Inc. (MBX) | Phase 3 |
Clinical Trials (1)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Followed by an Open-Label Extension to Evaluate the Safety and Efficacy of Canvuparatide (MBX 2109) in Adult Patients With Hypoparathyroidism
Primary endpoint: To evaluate the effect of pooled weekly doses of canvuparatide on the proportion of responder patients at week 26.
Frequently asked questions
Who is developing canvuparatide?
canvuparatide is being developed by MBX Biosciences, Inc..
How many clinical trials involve canvuparatide?
BioSniper tracks 1 clinical trial involving canvuparatide.